Abstract: A WS12-releasing contact lens is described as well as method of manufacturing the same. The WS12-releasing contact lens comprises a polymeric lens body and WS12 releasably adhered to the polymeric lens body, and releases from 0.05 ?g to 0.5 ?g WS12 after 1 hour in a release media or when worn by a human subject. The WS12-releasing contact lens can be comfortably worn by a symptomatic contact lens wearer and can increase the duration of comfortable lens wearing time and/or reduce lens awareness events and/or reduce contact lens dryness in a symptomatic contact lens wearer.

Abstract: A WS12-releasing contact lens is described as well as method of manufacturing the same. The WS12-releasing contact lens comprises a polymeric lens body and WS12 releasably adhered to the polymeric lens body, and releases from 0.05 ?g to 0.5 ?g WS12 after 1 hour in a release media or when worn by a human subject. The WS12-releasing contact lens can be comfortably worn by a symptomatic contact lens wearer and can increase the duration of comfortable lens wearing time and/or reduce lens awareness events and/or reduce contact lens dryness in a symptomatic contact lens wearer.

Abstract: A contact lens having an amount of at least one cooling agent and at least one TRPV1 inhibitor releasably adhered is described as well as method of manufacturing the same. The contact lens can be comfortably worn by contact lens wearers and can increase the duration of comfortable lens wearing time and/or reduce lens awareness events and/or reduce contact lens dryness in a symptomatic contact lens wearer and further can reduce or avoid any stinging/burning sensation when the contact lens is first used or a short time thereafter.

Abstract: A WS12-releasing contact lens is described as well as method of manufacturing the same. The WS12-releasing contact lens comprises a polymeric lens body and WS12 releasably adhered to the polymeric lens body, and releases from 0.05 ?g to 0.5 ?g WS12 after 1 hour in a release media or when worn by a human subject. The WS12-releasing contact lens can be comfortably worn by a symptomatic contact lens wearer and can increase the duration of comfortable lens wearing time and/or reduce lens awareness events and/or reduce contact lens dryness in a symptomatic contact lens wearer.

Abstract: An oleic acid-releasing contact lens is described as well as method of manufacturing the same. The oleic acid-releasing contact lens contains oleic acid releasably adhered to the polymeric lens body, and releases from 2 ?g to 25 ?g oleic acid after 1 hour in a release media. The oleic acid-releasing contact lens can be comfortably worn by a symptomatic contact lens wearer, and can increase the duration of comfortable lens wearing time and/or reduce lens awareness events in a symptomatic contact lens wearer.

Abstract: A cationic contact lens is described as well as methods of manufacturing the same. The cationic contact lens includes a polymeric lens body that is the reaction product of a polymerizable composition that includes at least one siloxane, at least one nonionic hydrophilic monomer and at least one acyclic tertiary amine monomer. The cationic contact lens can be an unworn sterile silicone hydrogel contact lens. The contact lens is capable of substantially linear release of a releasable anionic agent and the at least one acyclic tertiary amine monomer facilitates uptake and/or sustained release of the releasable anionic agent by the polymeric lens body. The contact lens can be present in a sealed contact lens package.

Abstract: An ophthalmic composition for administration to an eye of a patient for the treatment of an ocular infection. The ophthalmic composition contains an ?-polylysine (?PL) in an amount effective to treat or control or prevent the ocular infection.

Abstract: An ophthalmic composition for administration to an eye of a patient for the treatment of an ocular infection. The ophthalmic composition contains an ?-polylysine (?PL) in an amount effective to treat or control or prevent the ocular infection.

Abstract: The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.

Abstract: The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.

Abstract: The invention provides methods for stabilizing amino-substituted steroid therapeutic agents in topical ophthalmic and other pharmaceutical formulations using effective stabilizing amounts of lightly cross-linked carboxy-containing polymers; Stabilized and stabilized/solubilized pharmaceutical compositions adapted for various routes of administration are also described.

Abstract: Methods and compositions for preventing or treating ophthalmic diseases or disorders wherein an ophthalmically effective amount of the C.sub.20 through C.sub.26 aminosteroids of formula XI and their pharmaceutical, acceptable salts, hydrates or solvates is administered in an inert vehicle to arrest oxidation processes damaging to the eye.

Abstract: Methods and compositions for preventing or treating ophthalmic diseases or disorders wherein an ophthalmically effective amount of the C.sub.20 through C.sub.26 aminosteroids of formula XI and their pharmaceutical, acceptable salts, hydrates or solvates is administered in an inert vehicle to arrest oxidation processes damaging to the eye.

Abstract: Methods and compositions for preventing or treating ophthalmic diseases or disorders wherein an ophthalmically effective amount of the C.sub.20 through C.sub.26 aminosteroids of formula XI and their pharmaceutical, acceptable salts, hydrates or solvates is administered in an inert vehicle to arrest oxidation processes damaging to the eye.